Figure 4

Effects of MAPK inhibitorsin vivo. Actively intraperitoneally sensitized mice were challenged by intranasally administration of ovalbumin. SB203580 (Figure A), SP600125 (Figure B) and U0126 (Figure C) were given intraperitoneally two hours prior to ovalbumin challenge. After 4 days of challenge bronchoalveolar lavage was performed. Total cell number in BAL and differential cell count on cytospin preparations was assessed. OVA challenged vehicle-treated animals were taken as a positive control. Each column represents mean ± s.e.mean. n = 5 mice per group. *p < 0.05 (drug treated versus OVA challenged vehicle (positive) control), **p < 0.005 (drug treated versus OVA challenged vehicle (positive) control). ⁺⁺ p < 0.005 (OVA challenged (positive) versus saline challenged (negative) control).